Your session is about to expire
← Back to Search
Sacituzumab Govitecan for Brain Tumor
Study Summary
This trial is testing a new drug to see if it can shrink brain tumors before surgery. The drug will be given before surgery, and then during surgery, doctors will take out some of the tumor to test.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 529 Patients • NCT02574455Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My glioblastoma has returned and worsened after standard treatment.My kidneys work well enough, with a creatinine clearance rate of at least 30 mL/min.I am 18 years old or older.You are expected to live for at least 3 more months.I haven't taken seizure medications like carbamazepine or phenytoin in the last 14 days.I can take care of myself but might not be able to do heavy physical work.You have a heart condition that shows up on an ECG test, including a long QT interval or risk factors for a specific type of heart rhythm problem.I have had a recent brain bleed or tumor bleed, confirmed by MRI or CT scan.I do not have serious heart disease or recent heart attacks.I have recovered from previous treatment side effects.You need to have a certain level of white blood cells, platelets, and hemoglobin in your blood.My liver function tests are within the required range.I haven't taken any cancer treatment drugs or had Sacituzumab Govitecan in the last 21 days.My breast cancer has spread to my brain.I am scheduled for a craniotomy as part of my treatment plan.My only cancerous lesion was treated with targeted radiation in the last 3 months.I am on warfarin or similar blood thinners and cannot switch to LMWH before starting the study drug.
- Group 1: Breast Brain Metastasis and Glioblastoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total enrollment figure for this trial?
"Affirmative. Clinicaltrials.gov has verified that this clinical trial is currently enrolling participants, with the first post being uploaded on July 17th 2019 and last modified on May 17th 2022. The research team must recruit 20 patients from one site for completion of the study."
What is the typical purpose of administering Sacituzumab Govitecan?
"Sacituzumab Govitecan is the usual treatment for this medical intervention, but it has proven to be efficacious in treating other ailments such as pharmacotherapy, uc 84572, and breast."
Is this medical research enrolling participants at the moment?
"This clinical trial, which was published on July 17th 2019 and last modified on May 17th 2022 according to the data found in clinicaltrials.gov, is currently looking for suitable candidates."
Is this particular medical experiment a pioneering endeavor?
"Research into Sacituzumab Govitecan began in 2018, with the initial clinical trial sponsored by Hoffmann-La Roche. After successful completion of Phase 1 & 2 trials involving 435 participants, 33 active studies are now being conducted around the world in 418 cities across 32 nations."
Are there any other investigations into the efficacy of Sacituzumab Govitecan?
"Presently, the research into Sacituzumab Govitecan comprises 33 active clinical trials. Of these studies, 5 are within Phase 3. Most of them take place in Birmigham and Massachusetts; however, there is a grand total of 1398 sites running investigations for this therapeutic remedy."
Share this study with friends
Copy Link
Messenger